Exploring the Molecular Targets for Breast Cancer Therapy
Abstract
Twenty one human breast cancer lines were screened for expression of various RPTK including ErbB2, EGF, IGF-1 and insulin receptors. Those lines displayed a wide spectrum of colony forming and invasion activity. ErbB2 over expressing cells displayed an increased sensitivity toward inhibitors of the P13 kinase signaling pathway including rapamycin for monolayer and anchorage independent growth. Forced expression of ErbB2 in the non-ErbB2 over-expressing cells was able to confer the rapamycin hypersensitivity of those cells for anchorage independent growth. Rapamycin and herceptin additively inhibited adherent and anchorage independent growth of ErbB2 over-expressing breast cancer cells. An ErbB2 transgenic mouse model and the nude mouse xenograft model were used to test the tumor inhibitory effect of rapamycin and herceptin. Our result showed that rapamycin and herceptin each displayed a significant inhibition, and together demonstrated an additive inhibition, of tumor growth and tumor incidence, and thus combination of the two drugs could offer an improved anti-breast cancer therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2005
- Accession Number
- ADA442297
Entities
People
- Lu-hai Wang
Organizations
- Icahn School of Medicine at Mount Sinai